About
Profile
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
ICLR
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- Icon Q4 2023 Earnings Preview
- ICON forecasts up to 8% revenue growth for 2024
- Growth at a reasonable price stocks for 2024 - Jefferies
- Icon GAAP EPS of $1.97 misses by $0.01, revenue of $2.05B in-line
- Icon Q3 2023 Earnings Preview
- ICON a new buy at TD Cowen on clinical landscape
- ICON in pact with BARDA for next-gen COVID vaccine trial
- Regeneron, J&J receive millions to develop new COVID therapies
- Icon Non-GAAP EPS of $3.11 beats by $0.03, revenue of $2.02B in-line
- Icon Q2 2023 Earnings Preview
- What’s next for clinical research firms after pandemic boom?
- FDA to broaden access to decentralized clinical trials
- Iqvia, Icon lag contract research rivals after Q1 earnings
- Icon reports Q1 earnings; reaffirms FY23 outlook
- Icon Q1 2023 Earnings Preview
- LEO Pharma and ICON to scale clinical trial within medical dermatology
- Icon Non-GAAP EPS of $3.13 beats by $0.08, revenue of $1.96B in-line
- Icon Q4 2022 Earnings Preview
- ICON FY23 revenue to be in-line with consensus, EPS above consensus
- ICON upgraded to buy at BofA on core growth, deal synergies